Syntagon, a contract research organisation (CRO) based in Stockholm, Sweden, has opened new premises in Shanghai, China to improve the cost-effectiveness of its raw material sourcing for clinical trials.

Sourcing raw materials can be a significant cost component in clinical development, Syntagon pointed out. It said the Shanghai office would enable the company to deliver materials more rapidly and at more attractive prices.

“By having a presence on the ground in Shanghai, we have direct access to many raw material suppliers, thereby avoiding agents and middlemen, and reducing delivery time,” explained Syntagon’s chief executive officer, Michael Lofthagen.

The new office will complement existing operations in Södertälje, Sweden and Riga, Latvia.

Founded in 1998 by former personnel from AstraZeneca, Syntagon focuses on drug development from lead optimisation through to Phase II clinical trials.